Prostate Cancer Therapeutics Market by Drug Types (Hormonal Therapy [Luteinizing Hormone-Releasing Hormone Antagonists {Zytiga and Gonax}, Luteinizing Hormone-Releasing Hormone Agonists {Lupron, Zoladex, Eligard, Decapeptyl, Vantas, and Others}, and Anti-Androgen {Xtandi, and Casodex}], Chemotherapy [Taxotere and Jevtana], Immunotherapy [Provenge], and Targeted Therapy [Xofigo]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global prostate cancer therapeutics market size is expected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising incidences of prostate cancer.

Prostate cancer refers to a type of cancer that originates in the prostate gland and is one of the most common types of cancer. The cancer grows slowly and spread around the prostate gland. The exact reason for prostate cancer formation is not yet known; however, some symptoms such as obesity, history of any other tumorous growth, and overweight can be related to the cancer type. Some patients with cardiovascular diseases are expected to suffer from metastasis cancer too. The raid development of multi-parametric technology and diagnostic methods are expected to improve the detection of tumors and can confirm whether there is a requirement for tissue biopsy. Many inclusive cancer therapeutic products are expected to be introduced in the market owing to the increasing number of expiry of patents of the key existing products in the coming years.

Market Trends, Drivers, Restraints, and Opportunities

• Rising adoption of innovative technology for cancer treatment and large update in screening & diagnostic test techniques are projected to drive the market growth. 
• Governments across developed countries are taking initiatives to conduct & execute programs for creating awareness of screening tests. This presents a key driving factor of the market. 
• Massive engagement of major market players in research and development activities to develop advanced therapeutic products for the treatment of such tumors are some major factors boosting the market expansion.
• High costs linked with tissue biopsy and consulting fees of the medical practitioner along with poor reimbursement of treatment costs are expected to hinder the market growth.

Scope of the Report                         

The report on the global prostate cancer therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Hormonal therapy segment is expected to register a high CAGR

Based on drug types, the global prostate cancer therapeutics market is segmented into hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. The hormonal therapy segment is further divided into luteinizing hormone-releasing hormone antagonists, luteinizing hormone-releasing hormone agonists, and anti-androgen. The luteinizing hormone-releasing hormone antagonists segment is further bifurcated into zytiga and gonax. The luteinizing hormone-releasing hormone agonists consists of lupron, zoladex, eligard, decapeptyl, vantas, and others while the anti-androgen segment includes xtandi and casodex. The chemotherapy segment is sub-divided into taxotere and jevtana while the immunotherapy segment consists of provenge and the targeted therapy segment consists of xofigo. The hormonal therapy segment accounted for a key share of the market in 2019 and is expected to register a high CAGR during the projected period owing to the development and adoption of hormonal class drug. However, the targeted therapy segment is anticipated to expand at a rapid pace during the forecast period due to their effectiveness and technology advancement for the targeted therapy.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share during the projected period owing to the increasing number of investments for research and development by major market players. Moreover, the presence of key global players in the region and their early adoption of advanced technology for the cancer treatment are major driving factors of the regional market. Meanwhile, the market of Asia Pacific is projected to hold a major market share during the forecast period due to rising expansion of cancer treatment facilities and growing awareness of such tumors among patients in the region.

Segments

Segments Covered in the Report

The global prostate cancer therapeutics market has been segmented on the basis of

Drug Types

• Hormonal Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
    • Zytiga
    • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
    • Lupron
    • Zoladex
    • Eligard
    • Decapeptyl
    • Vantas
    • Others
  • Anti-Androgen
    • Xtandi
    • Casodex
• Chemotherapy
  • Taxotere
  • Jevtana
• Immunotherapy
  • Provenge
• Targeted Therapy
  • Xofigo

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Johnson & Johnson
• Astella Pharma, Inc.
• Sanofi
• Ipsen
• Bayer Cropscience Limited
• AstraZeneca plc.
• Valeant Pharmaceuticals North America LLC

Competitive Landscape

Key players competing in the global prostate cancer therapeutics market are Johnson & Johnson; Astella Pharma, Inc.; Sanofi; Ipsen; Bayer Cropscience Limited; AstraZeneca plc; and Valeant Pharmaceuticals North America LLC. The main market players are continuously engaged in range of the business development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to strive for accelerating their business expansion in the market.